NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

Equities research analysts at StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

Shares of NURO opened at $3.81 on Friday. The company has a market capitalization of $7.77 million, a PE ratio of -0.83 and a beta of 2.18. NeuroMetrix has a one year low of $2.66 and a one year high of $4.73. The company’s fifty day moving average price is $4.09 and its 200 day moving average price is $3.84.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings data on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. The business had revenue of $0.59 million during the quarter. During the same quarter in the previous year, the firm earned ($1.66) EPS.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.